ESG Tracker
  • Companies
  • Rankings
  • Portfolios
  • My Portfolios
  • Log In Log Out
  • Contact

← Back to search

ALKERMES PUBLIC LIMITED COMPANY

ALKS · NASDAQ

Pharmaceutical Preparation Manufacturing

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

ESG Overview

Overall: BBB (High)
E: BBBS: BBG: BB

ESG grades from public dataset.

ESG data: Public Company ESG Ratings (CC BY-NC-SA 4.0)

Market Data

Price $28.23 -0.22 (-0.77%)
Market Cap$4.74B
P/E Ratio19.62
EPS$—
52W High$36.32
52W Low$25.17
Beta0.44

Data from Finnhub · Updated Mar 10, 2026

Products and Services
  • Company Search
  • Rankings
  • Portfolios
About ESG Tracker
  • FAQ
Legal & Security
  • Disclosures
  • Privacy Policy
Contact
  • Contact Us
ESG Tracker

ESG Tracker is for informational purposes only and does not constitute investment advice. The operator of this site is not a registered investment advisor. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.

Public ESG data sourced from Public Company ESG Ratings Dataset by esgcompare.org, licensed under CC BY-NC-SA 4.0. This site is non-commercial and for informational purposes only.